Skip to main content
    • Aa
    • Aa

Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report

  • A. A. Nierenberg (a1), M. M. Husain (a2), M. H. Trivedi (a2), M. Fava (a1), D. Warden (a2), S. R. Wisniewski (a3), S. Miyahara (a3) and A. J. Rush (a4)...

Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.


Participants in primary (n=18) and psychiatric (n=23) practice settings were openly treated with citalopram using measurement-based care for up to 14 weeks and follow-up for up to 1 year. We assessed 943 (32.8% of 2876) participants who met criteria for remission to determine the proportions with individual residual symptoms and any of the nine DSM-IV criterion symptom domains to define a major depressive episode. At each visit, the 16-item Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR16) and the self-report Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale were used to assessed depressive symptoms and side-effects respectively.


More than 90% of remitters had at least one residual depressive symptom (median=3). The most common were weight increase (71.3%) and mid-nocturnal insomnia (54.9%). The most common residual symptom domains were sleep disturbance (71.7%) and appetite/weight disturbance (35.9%). Those who remitted before 6 weeks had fewer residual symptoms at study exit than did later remitters. Residual sleep disturbance did not predict relapse during follow-up. Having a greater number of residual symptom domains was associated with a higher probability of relapse.


Patients with remission of MDD after treatment with citalopram continue to experience selected residual depressive symptoms, which increase the risk of relapse.

Corresponding author
*Address for correspondence: A. A. Nierenberg, M.D., Massachusetts General Hospital, Suite 580, 50 Staniford Street, Boston, MA 02114, USA. (Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

C Bockting , P Spinhoven , M Koeter , L Wouters , A Schene ; Depression Evaluation Longitudinal Therapy Assessment (DELTA) Study Group (2006). Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. Journal of Clinical Psychiatry 67, 747755.

CE Carney , ZV Segal , JD Edinger , AD Krystal (2007). A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. Journal of Clinical Psychiatry 68, 254260.

C DeBattista , K Doghramji , M Menza , M Rosenthal , R Fieve (2003). Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. Journal of Clinical Psychiatry 64, 10571064.

GA Fava , S Fabbri , N Sonino (2002). Residual symptoms in depression: an emerging therapeutic target. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26, 10191027.

M Fava , AJ Rush , MH Trivedi , AA Nierenberg , ME Thase , HA Sackeim , FM Quitkin , S Wisniewski , PW Lavori , JF Rosenbaum , DJ Kupfer (2003). Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatric Clinics of North America 26, 457494.

M Fava , ME Thase , C DeBattista (2005). A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Journal of Clinical Psychiatry 66, 8593.

M Hamilton (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278296.

LL Judd , HS Akiskal , JD Maser , PJ Zeller , J Endicott , W Coryell , MP Paulus , JL Kunovac , AC Leon , TI Mueller , JA Rice , MB Keller (1998 a). Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders 50, 97–108.

LL Judd , HS Akiskal , JD Maser , PJ Zeller , J Endicott , W Coryell , MP Paulus , JL Kunovac , AC Leon , TI Mueller , JA Rice , MB Keller (1998 b). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Archives of General Psychiatry 55, 694700.

N Kennedy , E Paykel (2004). Residual symptoms at remission from depression: impact on long-term outcome. Journal of Affective Disorders 80, 135144.

AC Leon , PM Marzuk , K Tardiff , A Bucciarelli , M Stajic , TM Piper , S Galea (2007). Antidepressants in adult suicides in New York City: 2001–2004. Journal of Clinical Psychiatry 68, 13991403.

J Mintz , LI Mintz , MJ Arruda , SS Hwang (1992). Treatments of depression and the functional capacity to work. Archives of General Psychiatry 49, 761768.

AA Nierenberg , BR Keefe , VC Leslie , JE Alpert , JA Pava , JJ Worthington , JF Rosenbaum , M Fava (1999). Residual symptoms in depressed patients who respond acutely to fluoxetine. Journal of Clinical Psychiatry 60, 221225.

AJ Rush , IH Bernstein , MH Trivedi , TJ Carmody , S Wisniewski , JC Mundt , K Shores-Wilson , MM Biggs , A Woo , AA Nierenberg , M Fava (2006 a). An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biological Psychiatry 59, 493501.

AJ Rush , HC Kraemer , HA Sackeim , M Fava , MH Trivedi , E Frank , PT Ninan , ME Thase , AJ Gelenberg , DJ Kupfer , DA Regier , JF Rosenbaum , O Ray , AF Schatzberg (2006 b). Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology 31, 18411853.

GE Simon (2006). How can we know whether antidepressants increase suicide risk? American Journal of Psychiatry 163, 18611863.

MH Trivedi , AJ Rush , SR Wisniewski , AA Nierenberg , D Warden , L Ritz , G Norquist , RH Howland , B Lebowitz , PJ McGrath , K Shores-Wilson , MM Biggs , GK Balasubramani , M Fava (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 2840.

SR Wisniewski , AJ Rush , GK Balasubramani , MH Trivedi , AA Nierenberg , for the STAR*D Investigators (2006). Self-rated global measure of the frequency, intensity, and burden of side effects. Journal of Psychiatric Practice 12, 7179.

M Zimmerman , MA Posternak , I Chelminski (2007). Heterogeneity among depressed outpatients considered to be in remission. Comprehensive Psychiatry 48, 113117.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 11
Total number of PDF views: 204 *
Loading metrics...

Abstract views

Total abstract views: 862 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st September 2017. This data will be updated every 24 hours.